Ichthyosis- Pipeline Insight, 2019
This report can be delivered to the clients within 48 Hours
'Ichthyosis- Pipeline Insight, 2019' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ichthyosis pipeline landscape is provided which includes the disease overview and Ichthyosis treatment guidelines. The assessment part of the report embraces, in depth Ichthyosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ichthyosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Ichthyosis Understanding
Ichthyosis, also known as disorders of keratinization (DOK), encompass a heterogeneous group of skin diseases linked by the common finding of abnormal barrier function, which initiates a default compensatory pathway of hyperproliferation. The unifying phenotypic feature of the ichthyosis is the clinical manifestation of localized and/or generalized scaling. Other include erythroderma, palmoplantar keratoderma, hypohidrosis, and recurrent infections. Most known forms of ichthyosis are a rare genetic disorder, which are hereditary in nature (some forms are dominant and some are recessive). Although ichthyoses are primarily inherited disorders with onset at or shortly after birth, rare acquired forms have been reported in the setting of malignancy, nutritional deficiency, and autoimmune or infectious disease. Mutations in over 50 genes have been reported to cause ichthyoses and these affect a host of cellular functions including DNA repair, lipid biosynthesis, adhesion, and desquamation as well as other pathways. Ichthyosis vulgaris (IV) and X-linked recessive ichthyosis (XLRI) are classified as the “common ichthyoses”, given their high prevalence.
Ichthyosis Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Ichthyosis targeted therapeutics development with respective active and dormant or discontinued projects Ichthyosis pipeline report covers 11+ companies. Some of the key players include Mayne Pharma/Galderma (Trifarotene), Patagonia Pharmaceuticals (PAT-001), Exicure (XCUR 17), etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Ichthyosis Analytical Perspective by DelveInsight
SCOPE OF THE REPORT
'Ichthyosis- Pipeline Insight, 2019' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ichthyosis pipeline landscape is provided which includes the disease overview and Ichthyosis treatment guidelines. The assessment part of the report embraces, in depth Ichthyosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ichthyosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Ichthyosis Understanding
Ichthyosis, also known as disorders of keratinization (DOK), encompass a heterogeneous group of skin diseases linked by the common finding of abnormal barrier function, which initiates a default compensatory pathway of hyperproliferation. The unifying phenotypic feature of the ichthyosis is the clinical manifestation of localized and/or generalized scaling. Other include erythroderma, palmoplantar keratoderma, hypohidrosis, and recurrent infections. Most known forms of ichthyosis are a rare genetic disorder, which are hereditary in nature (some forms are dominant and some are recessive). Although ichthyoses are primarily inherited disorders with onset at or shortly after birth, rare acquired forms have been reported in the setting of malignancy, nutritional deficiency, and autoimmune or infectious disease. Mutations in over 50 genes have been reported to cause ichthyoses and these affect a host of cellular functions including DNA repair, lipid biosynthesis, adhesion, and desquamation as well as other pathways. Ichthyosis vulgaris (IV) and X-linked recessive ichthyosis (XLRI) are classified as the “common ichthyoses”, given their high prevalence.
Ichthyosis Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Ichthyosis targeted therapeutics development with respective active and dormant or discontinued projects Ichthyosis pipeline report covers 11+ companies. Some of the key players include Mayne Pharma/Galderma (Trifarotene), Patagonia Pharmaceuticals (PAT-001), Exicure (XCUR 17), etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Ichthyosis Analytical Perspective by DelveInsight
- In-depth Ichthyosis Commercial Assessment of products
- Ichthyosis Clinical Assessment of products
SCOPE OF THE REPORT
- The Ichthyosis report provides an overview of therapeutic pipeline activity for Ichthyosis across the complete product development cycle including all clinical and non-clinical stages
- It comprises of detailed profiles of Ichthyosis therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
- Detailed Ichthyosis Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Ichthyosis
- Establish a comprehensive understanding of the current pipeline scenario across Ichthyosis to formulate effective R&D strategies
- Assess challenges and opportunities that influence Ichthyosis R&D
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Get in detail information of each product with updated information on each project along with key milestones
- Devise Ichthyosis in licensing and out licensing strategies by identifying prospective partners with progressing projects for Ichthyosis to enhance and expand business potential and scope
- Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
1. REPORT INTRODUCTION
2. ICHTHYOSIS
2.1. Ichthyosis Disease Overview
2.2. Ichthyosis History
2.3. Ichthyosis Symptoms
2.4. Ichthyosis Causes
2.5. Ichthyosis Pathophysiology
2.6. Ichthyosis Diagnosis
2.6.1. Diagnostic Guidelines
3. ICHTHYOSIS CURRENT TREATMENT PATTERNS
3.1. Treatment Guidelines
4. ICHTHYOSIS - DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Ichthyosis companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Ichthyosis Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Ichthyosis Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. ICHTHYOSIS PIPELINE THERAPEUTICS
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. ICHTHYOSIS - PRODUCTS ANALYSIS
6.1. Product Profiles
6.1.1. Trifarotene - Galderma
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. PAT-001- Patagonia Pharmaceuticals
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
6.1.3. XCUR 17- Exicure
6.1.3.1. Product Description
6.1.3.1.1. Product Overview
6.1.3.1.2. Mechanism of Action
6.1.3.2. Research and Development
6.1.3.2.1. Clinical Studies
6.1.3.2.1.1. Detailed Study Description
6.1.3.2.1.2. Study Results
6.1.3.2.1.3. Clinical Trials: Tabular View
6.1.3.3. Product Development Activities
6.1.3.3.1. Tabulated Product Summary
6.1.3.3.1.1. General Description Table
7. RECENT TECHNOLOGIES
8. ICHTHYOSIS KEY COMPANIES
8.1. Patagonia Pharmaceuticals
8.2. Cellegy Pharmaceuticals
8.3. Mayne Pharma/Galderma
8.4. Janssen Pharmaceutica
8.5. Foamix
8.6. DermaXon
8.7. Aldeyra Therapeutics
8.8. Azitra
8.9. Krystal Biotech
8.10. Exicure
8.11. Galderma
9. ICHTHYOSIS KEY PRODUCTS
9.1. Isotretinoin
9.2. Monolaurin
9.3. Trifarotene
9.4. Liarozole
9.5. Ammonium lactate
9.6. DX 0386
9.7. Reproxalap
9.8. DX 0308
9.9. Research programme: skin disorder therapeutics
9.10. KB105
9.11. XCUR
9.12. Trifarotene
10. DORMANT AND DISCONTINUED PRODUCTS
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. ICHTHYOSIS - UNMET NEEDS
12. ICHTHYOSIS - FUTURE PERSPECTIVES
13. APPENDIX
14. REPORT METHODOLOGY
14.1. Secondary Research
14.2. Expert Panel Validation
2. ICHTHYOSIS
2.1. Ichthyosis Disease Overview
2.2. Ichthyosis History
2.3. Ichthyosis Symptoms
2.4. Ichthyosis Causes
2.5. Ichthyosis Pathophysiology
2.6. Ichthyosis Diagnosis
2.6.1. Diagnostic Guidelines
3. ICHTHYOSIS CURRENT TREATMENT PATTERNS
3.1. Treatment Guidelines
4. ICHTHYOSIS - DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Ichthyosis companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Ichthyosis Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Ichthyosis Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. ICHTHYOSIS PIPELINE THERAPEUTICS
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. ICHTHYOSIS - PRODUCTS ANALYSIS
6.1. Product Profiles
6.1.1. Trifarotene - Galderma
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. PAT-001- Patagonia Pharmaceuticals
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
6.1.3. XCUR 17- Exicure
6.1.3.1. Product Description
6.1.3.1.1. Product Overview
6.1.3.1.2. Mechanism of Action
6.1.3.2. Research and Development
6.1.3.2.1. Clinical Studies
6.1.3.2.1.1. Detailed Study Description
6.1.3.2.1.2. Study Results
6.1.3.2.1.3. Clinical Trials: Tabular View
6.1.3.3. Product Development Activities
6.1.3.3.1. Tabulated Product Summary
6.1.3.3.1.1. General Description Table
7. RECENT TECHNOLOGIES
8. ICHTHYOSIS KEY COMPANIES
8.1. Patagonia Pharmaceuticals
8.2. Cellegy Pharmaceuticals
8.3. Mayne Pharma/Galderma
8.4. Janssen Pharmaceutica
8.5. Foamix
8.6. DermaXon
8.7. Aldeyra Therapeutics
8.8. Azitra
8.9. Krystal Biotech
8.10. Exicure
8.11. Galderma
9. ICHTHYOSIS KEY PRODUCTS
9.1. Isotretinoin
9.2. Monolaurin
9.3. Trifarotene
9.4. Liarozole
9.5. Ammonium lactate
9.6. DX 0386
9.7. Reproxalap
9.8. DX 0308
9.9. Research programme: skin disorder therapeutics
9.10. KB105
9.11. XCUR
9.12. Trifarotene
10. DORMANT AND DISCONTINUED PRODUCTS
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. ICHTHYOSIS - UNMET NEEDS
12. ICHTHYOSIS - FUTURE PERSPECTIVES
13. APPENDIX
14. REPORT METHODOLOGY
14.1. Secondary Research
14.2. Expert Panel Validation
LIST OF TABLES
Table 1. Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Ichthyosis Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
Table 1. Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Ichthyosis Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
LIST OF FIGURES
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Ichthyosis companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Ichthyosis Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs
KEY COMPANIES
Patagonia Pharmaceuticals
Cellegy Pharmaceuticals
Mayne Pharma/Galderma
Janssen Pharmaceutica
Foamix
DermaXon
Aldeyra Therapeutics
Azitra
Bristol-Myers Squibb
Allergan
Chugai Pharmaceutical
Krystal Biotech
GlaxoSmithKline
Novartis
Teijin Pharma
Exicure
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Ichthyosis companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Ichthyosis Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs
KEY COMPANIES
Patagonia Pharmaceuticals
Cellegy Pharmaceuticals
Mayne Pharma/Galderma
Janssen Pharmaceutica
Foamix
DermaXon
Aldeyra Therapeutics
Azitra
Bristol-Myers Squibb
Allergan
Chugai Pharmaceutical
Krystal Biotech
GlaxoSmithKline
Novartis
Teijin Pharma
Exicure
